Guggenheim raised the firm’s price target on Assembly Biosciences (ASMB) to $39 from $31 and keeps a Buy rating on the shares. Following interim data from Assembly’s Phase 1b study released last month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results